Developments in Cardiovascular Medicine - Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia

Is Ambulatory Blood Pressure Monitoring Required to Define the Hypertensive Patient and to Detect Efficacy?

Developments in Cardiovascular Medicine - Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia ◽

10.1007/978-1-4613-1505-6_2 ◽

1990 ◽

pp. 13-24

Author(s):

William B. White

Keyword(s):

Blood Pressure ◽

Hypertensive Patient ◽

Ambulatory Blood Pressure Monitoring ◽

Ambulatory Blood Pressure ◽

Blood Pressure Monitoring ◽

Pressure Monitoring

Download Full-text

Testing the Relationship between Cholesterol Lowering and Cardiovascular Disease---Past, Present, and Prospects

Developments in Cardiovascular Medicine - Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia ◽

10.1007/978-1-4613-1505-6_14 ◽

1990 ◽

pp. 189-223

Author(s):

Robert I. Levy ◽

Conrad Blum

Keyword(s):

Cardiovascular Disease ◽

Cholesterol Lowering ◽

The Relationship

Download Full-text

Do We Need Any More Antihypertensive Drugs: The Validity of a Change in Blood Pressure as the Only Endpoint for Approvability

Developments in Cardiovascular Medicine - Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia ◽

10.1007/978-1-4613-1505-6_9 ◽

1990 ◽

pp. 103-105

Author(s):

N. M. Kaplan

Keyword(s):

Blood Pressure ◽

Antihypertensive Drugs

Download Full-text

What Have We Learned from Prior Clinical Trials of Antihypertensive Drug Therapy?

Developments in Cardiovascular Medicine - Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia ◽

10.1007/978-1-4613-1505-6_7 ◽

1990 ◽

pp. 93-96

Author(s):

Aram V. Chobanian

Keyword(s):

Clinical Trials ◽

Drug Therapy ◽

Antihypertensive Drug ◽

Antihypertensive Drug Therapy

Download Full-text

Are there Valid Surrogate Endpoints for Mortality that can be Used to Evaluate the Effects of Antiarrhythmic Drug Therapy?

Developments in Cardiovascular Medicine - Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia ◽

10.1007/978-1-4613-1505-6_12 ◽

1990 ◽

pp. 147-166

Author(s):

J. Thomas Bigger

Keyword(s):

Drug Therapy ◽

Antiarrhythmic Drug ◽

Surrogate Endpoints ◽

Antiarrhythmic Drug Therapy

Download Full-text

The Cost and Time to Develop a New Antihypertensive Drug Depending upon the Endpoint

Developments in Cardiovascular Medicine - Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia ◽

10.1007/978-1-4613-1505-6_10 ◽

1990 ◽

pp. 107-136

Author(s):

Harold K. Marder ◽

Gary Littman

Keyword(s):

Antihypertensive Drug ◽

The Cost

Download Full-text

How Does One Define Dose-Duration of an Antihypertensive Drug? What is the Role of Non-Mem and the Peak/Through Measurement?

Developments in Cardiovascular Medicine - Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia ◽

10.1007/978-1-4613-1505-6_6 ◽

1990 ◽

pp. 67-89

Author(s):

Raymond J. Lipicky

Keyword(s):

Antihypertensive Drug

Download Full-text

Clinical Trials of Antihypertensive Agents

Developments in Cardiovascular Medicine - Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia ◽

10.1007/978-1-4613-1505-6_5 ◽

1990 ◽

pp. 45-65

Author(s):

M. A. Weber ◽

J. M. Neutel ◽

D. H. G. Smith

Keyword(s):

Clinical Trials ◽

Antihypertensive Agents

Download Full-text

Is It Necessary to Demonstrate Changes in Left Ventricular Hypertrophy in the Evaluation of Antihypertensive Drugs?

Developments in Cardiovascular Medicine - Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia ◽

10.1007/978-1-4613-1505-6_4 ◽

1990 ◽

pp. 35-43

Author(s):

Thomas G. Pickering ◽

Richard B. Devereux

Keyword(s):

Left Ventricular Hypertrophy ◽

Ventricular Hypertrophy ◽

Antihypertensive Drugs ◽

Left Ventricular

Download Full-text

What Should be Required for FDA Approvability of a New Antihypertensive Drug? What is the FDA’s Viewpoint?

Developments in Cardiovascular Medicine - Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia ◽

10.1007/978-1-4613-1505-6_11 ◽

1990 ◽

pp. 139-146

Author(s):

R. Temple

Keyword(s):

Antihypertensive Drug

Download Full-text

Developments in Cardiovascular Medicine - Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia
Latest Publications

TOTAL DOCUMENTS

H-INDEX

Published By Springer US

Is Ambulatory Blood Pressure Monitoring Required to Define the Hypertensive Patient and to Detect Efficacy?

Testing the Relationship between Cholesterol Lowering and Cardiovascular Disease---Past, Present, and Prospects

Do We Need Any More Antihypertensive Drugs: The Validity of a Change in Blood Pressure as the Only Endpoint for Approvability

What Have We Learned from Prior Clinical Trials of Antihypertensive Drug Therapy?

Are there Valid Surrogate Endpoints for Mortality that can be Used to Evaluate the Effects of Antiarrhythmic Drug Therapy?

The Cost and Time to Develop a New Antihypertensive Drug Depending upon the Endpoint

How Does One Define Dose-Duration of an Antihypertensive Drug? What is the Role of Non-Mem and the Peak/Through Measurement?

Clinical Trials of Antihypertensive Agents

Is It Necessary to Demonstrate Changes in Left Ventricular Hypertrophy in the Evaluation of Antihypertensive Drugs?

What Should be Required for FDA Approvability of a New Antihypertensive Drug? What is the FDA’s Viewpoint?

Export Citation Format

Developments in Cardiovascular Medicine - Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and HypolipidemiaLatest Publications

TOTAL DOCUMENTS

H-INDEX

Published By Springer US

Is Ambulatory Blood Pressure Monitoring Required to Define the Hypertensive Patient and to Detect Efficacy?

Testing the Relationship between Cholesterol Lowering and Cardiovascular Disease---Past, Present, and Prospects

Do We Need Any More Antihypertensive Drugs: The Validity of a Change in Blood Pressure as the Only Endpoint for Approvability

What Have We Learned from Prior Clinical Trials of Antihypertensive Drug Therapy?

Are there Valid Surrogate Endpoints for Mortality that can be Used to Evaluate the Effects of Antiarrhythmic Drug Therapy?

The Cost and Time to Develop a New Antihypertensive Drug Depending upon the Endpoint

How Does One Define Dose-Duration of an Antihypertensive Drug? What is the Role of Non-Mem and the Peak/Through Measurement?

Clinical Trials of Antihypertensive Agents

Is It Necessary to Demonstrate Changes in Left Ventricular Hypertrophy in the Evaluation of Antihypertensive Drugs?

What Should be Required for FDA Approvability of a New Antihypertensive Drug? What is the FDA’s Viewpoint?

Developments in Cardiovascular Medicine - Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia
Latest Publications